Skip to main

The American Association for
Thoracic Surgery

Thoracic Surgical Oncology Group

In conjunction with the Fiona and Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center and the AATS, the Thoracic Surgery Oncology Group (TSOG) was formed in 2017 to support a network of North American thoracic surgery clinical trials relevant to physicians and their patients—something that had been missing from the landscape in recent years. The overarching goal of the group is to improve the understanding of thoracic oncologic diseases and enhance patient care through the administration of multi-site trials focused on recent advances in precision medicine, immunotherapy, and intraoperative imaging.

TSOG will actively accrue patients to relevant investigator-initiated clinical trials, as well as select industry-sponsored clinical trials, designed to improve outcomes for patients with thoracic malignancies. Learn more about joining the network and current RFA.

Executive Board

Chair

David R. Jones, MD

Memorial Sloan Kettering Cancer Center

Member

Raphael Bueno, MD

Brigham and Women's Hospital

Member

David H. Harpole, MD

Duke University

Member

Ara A. Vaporciyan, MD

The University of Texas MD Anderson Cancer Center

Current Sites and Principal Investigators

Allegheny General Hospital Cancer Center	Benny Weksler, MD
Baylor College of Medicine	Robert Taylor Ripley, MD
Brigham and Women’s Hospital	Raphael Bueno, MD
Cedars Sinai Medical Center	Harmik Soukiasian, MD
Centre Hospitalier de l’Université de Montréal (CHUM)	Moishe Liberman, MD
Duke University	David Harpole, MD
Endeavor Health	Seth Krantz, MD
Fox Chase Cancer Center	Stacy Su, MD
Hartford HealthCare	Brian Whang, MD
Massachusetts General Hospital	Michael Lanuti, MD
Mayo Clinic-Jacksonville	Ian Makey, MD
Mayo Clinic-Rochester	Dennis Wigle, MD
Memorial Sloan Kettering Cancer Center	David R. Jones, MD
NYU Grossman School of Medicine	Harvey Pass, MD
Research St. Joseph’s-Hamilton	Yaron Shargall, MD
Roswell Park Comprehensive Cancer Center	Sai Yendamuri, MD
Rush University Medical Center	Christopher W. Seder, MD
Stanford University	Douglas Liou, MD
The University of Texas MD Anderson Cancer Center	Ara Vaporciyan, MD
The Research Institute of McGill University Health Centre	Johnathan Spicer, MD
Thomas Jefferson University	Nathaniel R. Evans III, MD
University of Alabama at Birmingham	James Donahue, MD
University of Arizona	Stephanie Worrell, MD
University of California Los Angeles	Jay Moon Lee, MD
University of California San Diego	Mark Onaitis, MD
University of Chicago	Jessica Donington, MD
University Hospitals Cleveland Medical Center	Philip Linden, MD
University of Michigan	Jules Lin, MD
University of Minnesota	Ilitch Díaz Gutiérrez, MD
University of Pennsylvania	Doraid Jarrar, MD
University of Pittsburgh	James Luketich, MD
University of Southern California	Scott Atay, MD
University of Texas Southwestern	Inderpal Sarkaria, MD
University of Toronto (UHN)	Thomas Waddell, MD
Washington University in St. Louis	Benjamin Kozower, MD
Weill Cornell Medical College and The New York Presbyterian Hospital	Nasser K. Altorki, MD
West Virginia University	Jason Lamb, MD

TSOG 101

Dr. James M. Isbell, MD, MSCI, Memorial Sloan Kettering Cancer Center

Evaluation of perioperative circulating tumor DNA as a prognostic biomarker in patients undergoing neoadjuvant therapy for resectable non-small cell lung cancer.

The primary aim of this study is to determine the validity of using quantitative ctDNA as a surrogate marker for pathologic treatment response in patients receiving neoadjuvant therapy for stage IIA-IIIB NSCLC who are undergoing curative-intent resection

TSOG 102

Dr. James Huang, MD, Memorial Sloan Kettering Cancer Center

Registry trial of active surveillance for multifocalground glass opacities (GGOs).

The primary objective of this study is to determine lung cancer–specific survival at 5 years in patients undergoing active surveillance for GGOs.

TSOG 104

Dr. Harvey Pass, MD, New York University Langone Medical Center

A prospective, non interventional, trial evaluating the diagnostic accuracy of FBLN3 for mesothelioma pleural effusions.

The primary objective of this study is to prospectively create a virtual reference set of pleural effusion samples from patients referred for treatment of a pleural effusion which can be used for future biomarker discovery and validation studies.

TSOG 105

Benjamin D. Kozower, MD, MPH, Washington University in St. Louis Washington ; Varun Puri, MD, MS, Washington University in St. Louis ; Clifford Robinson, MD, Washington University in St. Louis

Comparing the effectiveness of surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer (SORT).

The primary objective of this study are to compare disease-free survival (DFS) and short – and long-term patient reported outcomes (PROs) between surgery and SBRT in stage I NSCLC patients.

TSOG 107

Paula Ugalde, MD, Brigham and Women’s Hospital

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens.

The primary objective of this study is to compare the number of stations and lymph nodes samples when adopting a standardized technique compared to the conventional (prior technique).

TSOG 108

David R. Jones, MD, Memorial Sloan Kettering Cancer Center ; Alper Toker, MD West Virginia University ; Scott Swanson, MD, Brigham and Women’s Hospital

Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry.

The primary objective of this study is to determine 3- and 5- year disease free survival (DFS) among patients undergoing pulmonary segmentectomy for clinical stage I lung cancer.

TSOG 109

David, R. Jones, MD, Memorial Sloan Kettering Cancer Center, AstraZeneca

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma NSCLC who are ctDNA-positive or High-risk Pathological Features (TROPION-Lung12).

To demonstrate superiority of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, following complete tumor resection, by assessment of DFS using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA- positive or have at least one high-risk pathological feature.

TSOG 110

James M. Isbell, MD, MSCI, Memorial Sloan Kettering Cancer Center, AstraZeneca

Phase II Trial of Neoadjuvant Trastuzumab Deruxtecan for Patients with Stage II-III HER2-Amplified or HER2-Mutated Non-Small Cell Lung Cancer (HERCULES).

Study to evaluate response rates to neoadjuvant trastuzumab deruxtecan (T-DXd) in resectable HER2-mutated or -amplified, clinical stage II-III NSCLC

TSOG 111

Nasser Altorki, MD, Weill Cornell Medicine, Regeneron

Multicenter randomized phase II trial of neoadjuvant radioimmunotherapy versus chemoimmunotherapy in patients with clinical stages IB-III (N2) non-small cell lung cancer.

To determine whether neoadjuvant focal SBRT combined with cemiplimab is associated with a higher rate of complete pathological response compared to chemotherapy plus cemiplimab.